Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Greenwich LifeSciences (GLSI) Income from Continuing Operations (2019 - 2025)

Greenwich LifeSciences filings provide 7 years of Income from Continuing Operations readings, the most recent being 4151845.0 for Q3 2025.

  • Quarterly Income from Continuing Operations fell 55.57% to 4151845.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 19475704.0 through Sep 2025, down 85.57% year-over-year, with the annual reading at 15788809.0 for FY2024, 77.57% down from the prior year.
  • Income from Continuing Operations hit 4151845.0 in Q3 2025 for Greenwich LifeSciences, down from 4025278.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 597008.0 in Q1 2021 and bottomed at 8040219.0 in Q4 2024.
  • Average Income from Continuing Operations over 5 years is 2553258.42, with a median of 2391789.0 recorded in 2023.
  • The largest annual shift saw Income from Continuing Operations plummeted 256.29% in 2021 before it rose 1.57% in 2023.
  • Greenwich LifeSciences' Income from Continuing Operations stood at 2360705.0 in 2021, then decreased by 18.21% to 2790512.0 in 2022, then increased by 1.57% to 2746739.0 in 2023, then plummeted by 192.72% to 8040219.0 in 2024, then skyrocketed by 48.36% to 4151845.0 in 2025.
  • Per Business Quant, the three most recent readings for GLSI's Income from Continuing Operations are 4151845.0 (Q3 2025), 4025278.0 (Q2 2025), and 3258362.0 (Q1 2025).